Next Capital Management LLC purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,067 shares of the company’s stock, valued at approximately $239,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Systematic Financial Management LP purchased a new position in Eli Lilly And Co in the 3rd quarter worth $2,123,000. MML Investors Services LLC grew its position in Eli Lilly And Co by 42.1% during the 3rd quarter. MML Investors Services LLC now owns 25,988 shares of the company’s stock worth $2,789,000 after purchasing an additional 7,698 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its position in Eli Lilly And Co by 145.0% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,818 shares of the company’s stock worth $732,000 after purchasing an additional 4,035 shares during the period. Rational Advisors LLC grew its position in Eli Lilly And Co by 790.2% during the 3rd quarter. Rational Advisors LLC now owns 14,350 shares of the company’s stock worth $1,540,000 after purchasing an additional 12,738 shares during the period. Finally, MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly And Co during the 3rd quarter worth about $201,000. Institutional investors and hedge funds own 77.00% of the company’s stock.
In other news, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $127.01, for a total transaction of $127,010.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Stephen F. Fry sold 14,847 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $123.16, for a total value of $1,828,556.52. Following the sale, the senior vice president now owns 109,663 shares in the company, valued at $13,506,095.08. The disclosure for this sale can be found here. Insiders have sold a total of 833,190 shares of company stock worth $102,388,102 over the last 90 days. Insiders own 0.11% of the company’s stock.
NYSE:LLY opened at $123.94 on Friday. Eli Lilly And Co has a 52 week low of $74.51 and a 52 week high of $130.75. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. The stock has a market cap of $128.33 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.49 and a beta of 0.33.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same quarter last year, the business earned $1.14 earnings per share. Eli Lilly And Co’s revenue was up 4.5% on a year-over-year basis. As a group, analysts expect that Eli Lilly And Co will post 5.62 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 8th. Stockholders of record on Friday, February 15th were given a dividend of $0.645 per share. The ex-dividend date of this dividend was Thursday, February 14th. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.08%. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.
Several equities research analysts have weighed in on LLY shares. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. UBS Group cut their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. Argus reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. BMO Capital Markets increased their price target on Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a research report on Monday, December 24th. They noted that the move was a valuation call. Finally, Citigroup downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 price target on the stock. in a research report on Sunday, December 2nd. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co currently has an average rating of “Buy” and a consensus price target of $113.06.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Google Finance
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.